Patents Represented by Attorney Eric Dichter

Find this attorney in the Justia Lawyer Directory

  • Method for treating psoriatic arthritis by administering an anti-IL-12 antibody
    Patent number: 8329171
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders, such as psoriatic arthritis.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: December 11, 2012
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Method for treating psoriasis by administering an anti-IL-12 antibody
    Patent number: 8329170
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in treating IL-12-related disorders, such as psoriasis.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: December 11, 2012
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Monkey homolog of human oncostatin M and methods of use thereof
    Patent number: 8309688
    Abstract: Cytokine oncostatin M nucleic acids from Cynomolgus monkey are useful for expression of oncostatin M proteins that are functional homologs of human oncostatin M. The nucleic acids and proteins produced therefrom are useful in screening and safety testing of oncostatin M, the generation and testing of oncostatin M modulators and related activities.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: November 13, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Adam Cotty, Michael Naso
  • Fibronectin type III domain based scaffold compositions, methods and uses
    Patent number: 8293482
    Abstract: A protein scaffold based on a consensus sequence of the tenth fibronectin type III (FN3) repeat from human fibronectin, including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG based on the consensus sequence have been identified as useful for diagnostic and/or therapeutic applications.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: October 23, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Steven Jacobs, Karyn O'Neil
  • Fibronectin type III domain based scaffold compositions, methods and uses
    Patent number: 8278419
    Abstract: A protein scaffold based on a consensus sequence of fibronectin type III (FN3) proteins, such as the tenth FN3 repeat from human fibronectin (human Tenascin), including isolated nucleic acids that encode a protein scaffold, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices. In particular, protein scaffold molecules binding to IgG have been identified as useful for diagnostic and/or therapeutic applications.
    Type: Grant
    Filed: October 27, 2009
    Date of Patent: October 2, 2012
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Steven Jacobs, Karyn O'Neil
  • CXCL13 antagonists and their use for the treatment of inflammatory diseases
    Patent number: 8277809
    Abstract: Methods of treating disorders related to CXCL13 activity utilize CXCL13 antagonists and, optionally, TNF? antagonists, such as antibodies, including specified portions or variants, polypeptides, polynucleotides, siRNA, shRNA, ribozymes, and DNAzymes. Disorders related to CXCL13 activity include inflammatory disorders, such as pulmonary disorders, for example, asthma, emphysema, and COPD, and systemic lupus erythematosus.
    Type: Grant
    Filed: April 20, 2007
    Date of Patent: October 2, 2012
    Assignee: Centocor, Inc.
    Inventors: Peter Bugelski, Anuk Das, Donald E. Griswold, Bailin Liang, Li Li, Robert T. Sarisky, Xiaozhou Shang
  • Anti-IL-6 antibodies, compositions, methods and uses
    Patent number: 8226611
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: July 24, 2012
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Methods of treatment using human anti-IL-23 antibodies
    Patent number: 8221760
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: June 30, 2011
    Date of Patent: July 17, 2012
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Nucleic acids encoding human anti-IL-23 antibodies
    Patent number: 8106177
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: January 31, 2012
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Nucleic acids encoding anti-IL-12 antibody
    Patent number: 8084233
    Abstract: Isolated anti-IL-12 antibodies, nucleic acids encoding antibodies or antibody portions, vectors, host cells, and methods of making are useful for production of antibody or portions for treating and/or diagnosing IL-12 related conditions, diseases, and disorders.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: December 27, 2011
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, David M. Knight, David Peritt, Bernard Scallon, David Shealy
  • Anti-IL-12 antibodies
    Patent number: 8080247
    Abstract: An anti-IL-12 antibody that binds to a portion of the IL-12 protein corresponding to at least one amino acid residue selected from the group consisting of residues 15, 17-21, 23, 40-43, 45-47, 54-56 and 58-62 of the amino acid sequence of the p40 subunit of IL-12, including isolated nucleic acids that encode at least one anti-IL-12 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: December 20, 2005
    Date of Patent: December 20, 2011
    Assignee: Janssen Biotech, Inc.
    Inventors: Jill Giles-Komar, George Heavner, David Knight, Jinquan Luo, David Peritt, Bernard Scallon, David Shealy
  • Methods of treating conditions using anti-IL-6 antibodies
    Patent number: 8067003
    Abstract: Anti-IL-6 antibodies are used to treat IL-6 related conditions, such as rheumatoid arthritis, osteoarthritis, osteolysis, aseptic loosening of orthopedic implants, systemic lupus erythematosus, cutaneous lupus erythematosus, lupus nephritis, type 2 diabetes mellitus, chronic obstructive pulmonary disease, and renal cell carcinoma.
    Type: Grant
    Filed: October 8, 2010
    Date of Patent: November 29, 2011
    Assignees: Centocor, Inc., Applied Molecular Evolution, Inc.
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • Method for detecting IL-16 activity and modulation of IL-16 activity based on rantes proxy protein levels
    Patent number: 8067191
    Abstract: Methods for detecting IL-16 biological activity, detecting modulation of IL-16 biological activity, and diagnosing the presence of or susceptibility of a subject to an IL-16-related disorder involve measuring and comparing the levels of RANTES proxy produced by eukaryotic cells, such as CD4+ and CD9+ cell lines, peripheral blood mononuclear cells, HuT-78 cells, and/or THP-1 cells.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: November 29, 2011
    Assignee: Centocor, Inc.
    Inventor: William G. Glass
  • Human anti-IL-23 antibodies, compositions, methods and uses
    Patent number: 7993645
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: August 12, 2010
    Date of Patent: August 9, 2011
    Assignee: Janssen Biotech, Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Methods for assessing response to therapy in subjects having ulcerative colitis
    Patent number: 7943310
    Abstract: A method for prognostic or diagnostic assessment of a gastrointestinal-related disorder, such as ulcerative colitis, in a subject correlates the presence, absence, and/or magnitude of a gene in a sample with a reference standard to determine the presence and/or severity of the disorder, and/or the response to treatment for the disorder. The method enables identification of the effectiveness of candidate therapies.
    Type: Grant
    Filed: August 30, 2007
    Date of Patent: May 17, 2011
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Xilin Li, Xiao-yu Song
  • Human anti-IL-23 antibodies, compositions, methods and uses
    Patent number: 7935344
    Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: December 28, 2006
    Date of Patent: May 3, 2011
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Jacqueline Benson, Jill Carton, Mark Cunningham, Yevgeniya I. Orlovsky, Robert Rauchenberger, Raymond Sweet
  • Cynomolgus gp80 receptor and uses thereof
    Patent number: 7931905
    Abstract: Isolated polynucleotides encoding cynomolgus monkey gp80, polypeptides obtainable from expression of these polynucleotides, compositions, recombinant cells, methods of making and using these polynucleotides, polypeptides, and compositions are useful in development of human therapeutics.
    Type: Grant
    Filed: May 21, 2009
    Date of Patent: April 26, 2011
    Assignee: Centocor Ortho Biotech Inc.
    Inventors: Michael Naso, Ronald Swanson, Bethany Swencki-Underwood
  • Anti-IL-6 antibody nucleic acid molecules and methods
    Patent number: 7833755
    Abstract: Anti-IL-6 antibody nucleic acids, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: May 22, 2009
    Date of Patent: November 16, 2010
    Inventors: Yan Chen, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-Yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot
  • IL-23p40 specific immunoglobulin derived proteins, compositions, epitopes, methods and uses
    Patent number: 7807471
    Abstract: An anti-IL-23 specific human Ig derived protein, isolated nucleic acids that encode at least one anti-IL-23 Ig derived protein, vectors, host cells, transgenic animals or plants, and methods of making and using thereof are useful as therapeutic and diagnostic compositions, methods and devices. The anti-IL-23 Ig derived protein preferably binds to one or more of the Seg 1, Seg 2, and Seg 3 epitopes of the p40 subunit of IL-23.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: October 5, 2010
    Assignee: Centocor Ortho Biotech, Inc.
    Inventors: Jacqueline Benson, Mark Cunningham, Jeffrey (Sinquan) Luo
  • Anti-IL-6 antibodies, compositions, methods and uses
    Patent number: RE43672
    Abstract: An anti-IL-6 antibody, including isolated nucleic acids that encode at least one anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: September 18, 2012
    Assignees: Janssen Biotech, Inc., Applied Molecular Evolution
    Inventors: Yan Chan, Debra Gardner, David M. Knight, Michael W. Lark, Bailin Liang, David J. Shealy, Xiao-yu R. Song, Vedrana Stojanovic-Susulic, Raymond W. Sweet, Susan H. Tam, Sheng-Jiun Wu, Jing Yang, David Matthew Marquis, Eric Michael Smith, Alain Philippe Vasserot